Correspondence 0001839882-23-019189 from Adamis Pharmaceuticals Corp (DMKPQ) (CIK 0000887247)
Adamis Pharmaceuticals Corp (DMKPQ) (CIK 0000887247)
Date: July 26, 2023 · CIK: 0000887247 · Accession: 0001839882-23-019189
AI Filing Summary & Sentiment
File numbers found in text: 333-273233
Letter
Adamis Pharmaceuticals Corporation
11683 El Camino Real, Suite 300
San Diego, CA 92103
July 26, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: Adamis Pharmaceuticals Corporation
Registration Statement on Form S-3 (No. 333-273233)
Filed on July 13, 2023
Acceleration Request
Requested Date: July 28, 2023
Requested Time: 9:00 A.M. Eastern Time
To Whom it May Concern:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Adamis Pharmaceuticals Corporation (the "Company") hereby requests that the effective date of the above referenced registration statement (the “Registration Statement”) be accelerated to July 28, 2023, at 9:00 a.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Weintraub Tobin Chediak Coleman Grodin, law corporation, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Securities Act of 1933, as amended.
Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Weintraub Tobin, by calling Kevin Kelso at (916) 558-6110.
Very truly yours,
Adamis Pharmaceuticals Corporation
Show Raw Text
CORRESP
1
filename1.htm
Adamis
Pharmaceuticals Corporation
11683 El Camino Real, Suite 300
San Diego, CA 92103
July
26, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re:
Adamis Pharmaceuticals Corporation
Registration Statement on Form S-3 (No. 333-273233)
Filed on July 13, 2023
Acceleration Request
Requested Date:
July 28, 2023
Requested Time:
9:00 A.M. Eastern Time
To Whom it May Concern:
Pursuant to Rule 461 promulgated under the Securities
Act of 1933, as amended, Adamis Pharmaceuticals Corporation (the "Company") hereby requests that the effective date of the above
referenced registration statement (the “Registration Statement”) be accelerated to July 28, 2023, at 9:00 a.m., Eastern Time,
or as soon thereafter as practicable, unless we or our outside counsel, Weintraub Tobin Chediak Coleman Grodin, law corporation, request
by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company
acknowledges that it is aware of its obligations under the Securities Act of 1933, as amended.
Once the Registration Statement has been declared effective,
please orally confirm that event with our counsel, Weintraub Tobin, by calling Kevin Kelso at (916) 558-6110.
Very truly yours,
Adamis Pharmaceuticals Corporation
By:
/s/ David J. Marguglio
David J. Marguglio
President